PH94B Neuroactive Nasal Spray, a Potential On-Demand Treatment for Social Anxiety Disorder | Learn how PH94B, a novel, rapid-acting CNS neuroactive nasal spray being developed by VistaGen Therapeutics for the treatment of
PDF) Effect of as-needed use of intranasal PH94B on social and performance anxiety in individuals with social anxiety disorder: L iebowitz et al.
VistaGen: Phase 2 Success In Anxiety Disorder, Phase 3 To Begin (NASDAQ:VTGN) | Seeking Alpha
PH94B Nasal Spray for Anxiety Disorders | Vistagen Therapeutics, Inc
VistaGen Therapeutics, Inc.
VistaGen's nasal spray wins US FDA fast-track designation for anxiety disorder | S&P Global Market Intelligence
Social Interaction Challenge, Minute-by-Minute Subjective Units of... | Download Scientific Diagram
Social Anxiety Disorder | Vistagen Therapeutics, Inc
:%0A%0APH94B%20Nasal%20Spray%20for%20Anxiety%20Disorders.png?md=1 "PH94B Nasal Spray for Anxiety Disorders Clinical Trial 2022 | Power")
PH94B Nasal Spray for Anxiety Disorders Clinical Trial 2022 | Power
VistaGen: Phase 2 Success In Anxiety Disorder, Phase 3 To Begin (NASDAQ:VTGN) | Seeking Alpha
Nasal spray to treat social anxiety disorder lacks abuse potential: FDA
VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder - BioTuesdays
VistaGen: Phase 2 Success In Anxiety Disorder, Phase 3 To Begin (NASDAQ:VTGN) | Seeking Alpha
U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder
PH94B Neuroactive Nasal Spray, a Potential On-Demand Treatment for Social Anxiety Disorder - YouTube
PH94B Nasal Spray for Anxiety Disorders | Vistagen Therapeutics, Inc
VistaGen Reports Positive Preclinical Data Differentiating Mechanism of Action of PH94B from Risk-Ridden Benzodiazepines
VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
vtgn10k_mar312020
